Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (9060)	12/19/2001 3:21:34 PM
From: Vector1	Respond to of 9719

<<arent you worried about a partnerschip for KOSP ?>> No, and I am not even convinced it is preferable if the terms are not favorable to KOSP. BMY did not want the drug. To know Phama companies is to know that these decisions are not always purely economic and always involve politics. The company has already proven they can sell to Niaspan into the cardio market. In fact scrips for Niaspan appear to have good momentum. They have $45m of new cash from BMY and even a small percentage of this enourmous maket is a home run for KOSP. V1